Inhibrx Biosciences INBX
NASDAQ INBX
$90.32 -0.29 (-0.32%)
As of: Nov 11, 2026 · 3:45 PM EST

Inhibrx Biosciences (INBX) Return on Capital Employed [ROCE] (2024 - 2026)

Updated

Inhibrx Biosciences (INBX) reported Return on Capital Employed [ROCE] of -101.62% for Q2 2026, down 12.99 percentage points from -88.63% a year earlier.

Analysis

Inhibrx Biosciences (INBX) Return on Capital Employed [ROCE] (2024 - 2026) Analysis & Trends

For FY2025, Inhibrx Biosciences posted Return on Capital Employed [ROCE] of -104.01%, up 58.79 percentage points from FY2024.

  • By year, Return on Capital Employed [ROCE] came in at -162.79% in FY2024.
  • Five-year quarterly Return on Capital Employed [ROCE] spans a low of -205.95% in Q4 2024 and a high of -88.63% in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Inhibrx Biosciences 1.33 Bn 760.41 Mn - -90.63%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -90.63%
Mar 31, 2026 -88.71%
Dec 31, 2025 -105.34%
Sep 30, 2025 -96.99%
Jun 30, 2025 -88.63%
Mar 31, 2025 -178.82%
Dec 31, 2024 -205.95%
Sep 30, 2024 -188.30%
API Access

Inhibrx Biosciences Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=INBX&period=max&api_key=YOUR_API_KEY